Aiming at mainstream markets, radiopharmaceutical partners engineer $260M cash deal

When Point Biopharma geared up to launch a Phase III trial for its PSMA-targeting radioligand therapy, one of the first things it did was to partner with Lantheus, the maker of a then-investigational PET imaging agent that can visualize the presence of the prostate-specific membrane antigen in patients.